Exenatide - An incretin mimetic agent for the treatment of type 2 diabetes;Exenatid - Ein inkretin-mimetikum zur behandlung des diabetes mellitus typ 2

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 11, 2007, Pages 571-574

  Reuter, Hans ^a   Erdmann, E ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antidiabetic therapy; Diabetes mellitus; Exenatide; GLP 1; Incretins; Insulin secretory pattern; Insulin glucagon ratio

Indexed keywords

DIGOXIN; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LISINOPRIL; METFORMIN; MEVINOLIN; PARACETAMOL; PLACEBO; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; INSULIN; PEPTIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VENOM;

ANOREXIA; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DYSPEPSIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING; AMINO ACID SEQUENCE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; GASTROINTESTINAL DISEASE; PHYSIOLOGY; STOMACH EMPTYING;

AMINO ACID SEQUENCE; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; GASTRIC EMPTYING; GASTROINTESTINAL DISEASES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PEPTIDES; RECEPTORS, GLUCAGON; SULFONYLUREA COMPOUNDS; VENOMS;

EID: 34047264607     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-970380     Document Type: Review

References (12)

1. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-47
2. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635
3. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100
4. Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158
5. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997
6. Heine RJ, Van Goal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143: 559-569
7. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091
8. King AB, Wolfe G, Healy S. Clinical observations of exenatide treatment. Diabetes Care 2006; 29: 1984
9. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089
10. Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50: 259-267
11. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613
12. Xu G, Staffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276